[1]MATTHEW EM，YANG Z，PERI S，et al.Plk2 loss commonly occurs in colorectal carcinomas but not adenomas：Relationship to mTOR signaling［J］.Neoplasia，2018，20(3)：244-255.
[2]YANG CK，GUAN S，YING MG.Effects of CO2 pneumoperitoneum on the expression of thymidine kinase 1 and Ki67 in colorectal carcinoma cells［J］.Sur Endoscopy，2014，28(10)：2863-2870.
[3]JEONG Y，HOANG NT，LOVEJOY A，et al.Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiotherapy response prediction［J］.Cancer Discovery，2017，7(1)：86-101.
[4]MARGARITESCU C，PIRICI D，CHERCIU I，et al.CD133/CD166/Ki-67 triple immunofluorescence assessment for putative cancer stem cells in colon carcinoma［J］.J Gastrointestin Liver Dis，2014，23(2)：161-170.
[5]TANG J，GUI C，QIU S，et al.The clinicopathological significance of Ki67 in papillary thyroid carcinoma：A suitable indicator［J］.World J Sur Oncol，2018，16(1)：100-102.
[6]TOMONO A，ITOH T，YANAGITA E，et al.Cell cycle kinetic analysis of colorectal neoplasms using a new automated immunohistochemistry-based cell cycle detection method［J］.Medicine，2015，94(4)：501-503.
[7]DEL GOBBO A，PELLEGRINELLI A，GAUDIOSO G，et al.Analysis of NSCLC tumour heterogeneity，proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas［J］.Histopathology，2016，68(5)：746-751.
[8]FABRIZIO FP，COSTANTINI M，COPETTI M，et al.Keap1/Nrf2 pathway in kidney cancer：Frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma［J］.Oncotarget，2017，8(7)：11187-11198.
[9]AKDEMIR B，NAKAJIMA Y，INAZAWA J.miR-432 induces NRF2 stabilization by directly targeting KEAP1［J］.Mol Cancer Res Mcr，2017，15(11)：1570-1572.
[10]KLAPPROTH E，DICKREUTER E，ZAKRZEWSKI F，et al.Whole exome sequencing identifies mTOR and KEAP1 as potential targets for radiosensitization of HNSCC cells refractory to EGFR and β1 integrin inhibition［J］.Oncotarget，2018，9(26)：18099-18114.
[11]SKOWRON MA，NIEGISCH G，ALBRECHT P，et al.Various mechanisms involve the nuclear factor(erythroid-derived 2)-like(NRF2) to achieve cytoprotection in long-term cisplatin-treated urothelial carcinoma cell lines［J］.Int J Mol Sci，2017，18(8)：1680-1682.
[12]HAYASHI M，GUIDA E，GOLDBERG R，et al.GULP1 is an epigenetically altered and functional tumor suppressor in urothelial carcinoma through regulation of Nrf2-Keap1 signaling axis［J］.Cancer Res，2017，77(13)：1551-1552.
[13]HONG F，FREEMAN ML，LIEBLER DC.Identification of sensor cysteines in human keap1 modified by the cancer chemopreventive agent sulforaphane［J］.Chemical Res Toxicology，2005，18(12)：1917-1926.
[14]HIDEFUMI SASAKI，AYUMI SUZUKI,MASAYUKI SHITARA,et al.Keap1 mutations in lung cancer patients［J］.Oncol Letters，2013，6(3)：719-721.
[15]WEI J，ZHANG Y，LUO Y，et al.Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2，Tgfβ1/2，and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice［J］.Free Radical Biol Med，2014，67(7)：91-102.
[16]HINTSALA HR，HAAPASAARI KM，SOINI Y，et al.An immunohistochemical study of NFE2L2，KEAP1 and 8-hydroxy-2'-deoxyguanosine and the EMT markers SNAI2，ZEB1 and TWIST1 in metastatic melanoma［J］.Histol Histopathol，2016，32(2)：11778-11779.